Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response.

Authors :: Bonifacio M
Binotto G
Maino E
Calistri E
Marin L
Scaffidi L
Frison L
De Marchi F
Krampera M
Semenzato G
Fanin R
Ambrosetti A
Tiribelli M
Source :: Haematologica [Haematologica] 2015 Aug; Vol. 100 (8), pp. e299-301. Date of Electronic Publication: 2015 Mar 27.
Publication Year :: 2015

Subjects :: Chromosome Aberrations
Fusion Proteins, bcr-abl genetics
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive mortality
Retrospective Studies
Time Factors
Treatment Outcome
Antineoplastic Agents therapeutic use
Imatinib Mesylate therapeutic use
Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics
Protein Kinase Inhibitors therapeutic use

Full Text Access

Tools